Neumora Therapeutics, Inc. Total Liabilities
Neumora Therapeutics, Inc. total liabilities. Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has total liabilities worth $45.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NMRA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neumora Therapeutics, Inc. (2019–2024)
Total liabilities of Neumora Therapeutics, Inc. from 2019 to 2024. This chart illustrates how Neumora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Neumora Therapeutics, Inc. strategic investment ratio to see how much of total assets are deployed in long-term investments.
Neumora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Flexopack Société Anonyme Commercial and Industrial Plastics Company
AT:FLEXO
|
Greece | €86.08 Million |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
USA | $2.99 Million |
|
Green Landscaping Group AB (publ)
ST:GREEN
|
Sweden | Skr4.60 Billion |
|
Mitake Information
TWO:8284
|
Taiwan | NT$849.50 Million |
|
Bank Dinar Indonesia Tbk PT
JK:DNAR
|
Indonesia | Rp10.47 Trillion |
|
Polymetals Resources Ltd
AU:POL
|
Australia | AU$78.47 Million |
|
Gelecek Varlik Yonetimi AS
IS:GLCVY
|
Turkey | TL530.35 Million |
|
Amorepacific Group
KO:002795
|
Korea | ₩1.39 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down Neumora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NMRA asset base.
Liquidity & Leverage Metrics
Neumora Therapeutics, Inc. Total Liabilities Ratios Explained
Neumora Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neumora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual total liabilities of Neumora Therapeutics, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $29.91 Million | +10.28% |
| 2023-12-31 | $27.12 Million | -96.89% |
| 2022-12-31 | $873.08 Million | +15.71% |
| 2021-12-31 | $754.52 Million | +158.10% |
| 2020-12-31 | $292.33 Million | +1391947.62% |
| 2019-12-31 | $21.00K | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more